TrialCardiovascular diabetology2017

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.

Thomas Jax et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.